Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage, classical Hodgkin lymphoma

Lancet. 2024 Jul 27;404(10450):312-313. doi: 10.1016/S0140-6736(24)01404-1.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brentuximab Vedotin / therapeutic use
  • Hodgkin Disease* / diagnostic imaging
  • Hodgkin Disease* / drug therapy
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / therapeutic use
  • Neoplasm Staging
  • Positron-Emission Tomography*

Substances

  • Brentuximab Vedotin
  • Immunoconjugates